Notes

European Journal of Clinical Microbiology and Infectious Diseases

, Volume 12, Issue 10, pp 778-782

First online:

Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy

  • W. LoAffiliated withDepartment of Medical Specialities, Section of Infectious Diseases, The University of Texas M.D. Anderson Cancer Center
  • , E. WhimbeyAffiliated withDepartment of Medical Specialities, Section of Infectious Diseases, The University of Texas M.D. Anderson Cancer Center
  • , L. EltingAffiliated withDepartment of Medical Specialities, Section of Infectious Diseases, The University of Texas M.D. Anderson Cancer Center
  • , R. CouchAffiliated withInfluenza Research Center, Baylor College of Medicine
  • , F. CabanillasAffiliated withDepartment of Hematology, Section of Lymphoma, The University of Texas M.D. Anderson Cancer Center
  • , G. BodeyAffiliated withDepartment of Medical Specialities, Section of Infectious Diseases, The University of Texas M.D. Anderson Cancer Center

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

A study was conducted to determine if a two-dose regimen of influenza vaccine would enhance the immunologic response of 41 patients with lymphoma receiving chemotherapy. Hemagglutinin-inhibiting antibody responses to influenza A/H1N1, A/H3N2 and B virus occurred in 32 %, 24 % and 20 % of patients following one dose, and in 49 %, 41 % and 46 % of patients following two doses, respectively. Responses to one or more vaccine components occurred in 42 % of patients after one dose and in 71 % after two doses. Fifty percent of the patients who did not respond after one dose responded after two doses. A two-dose regimen of influenza immunization may significantly enhance the response rate of cancer patients receiving chemotherapy.